Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 134 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with... April 26, 2023 Gut Microbes May Influence How Well Radiation Therapy Works against Cancer September 2, 2021 Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? August 20, 2024 Accepting Help During Cancer Is Hard, But It Can Benefit You... January 19, 2023 Load more HOT NEWS Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... Treatment with Tebentafusp Results in Longer Overall Survival Among Previously Untreated... FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma Woman Suffers Severe Eye Pain And Swelling, Finds Out She Has...
